WO2005114186A1 - ヒアルロン酸バインディングプロテインを用いたヒアルロン酸の測定方法 - Google Patents
ヒアルロン酸バインディングプロテインを用いたヒアルロン酸の測定方法 Download PDFInfo
- Publication number
- WO2005114186A1 WO2005114186A1 PCT/JP2005/008523 JP2005008523W WO2005114186A1 WO 2005114186 A1 WO2005114186 A1 WO 2005114186A1 JP 2005008523 W JP2005008523 W JP 2005008523W WO 2005114186 A1 WO2005114186 A1 WO 2005114186A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyaluronic acid
- habp
- reagent
- antibody
- latex particles
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/82—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a precipitate or turbidity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
Definitions
- the present invention relates to a method for measuring hyaluronic acid with excellent storage stability and high accuracy, and a reagent kit thereof.
- Hyaluronic acid is mainly contained in connective tissues such as animal joint fluid, eye glass fluid, umbilical cord, and dermis surface layer. Its blood concentration is known to increase during rheumatism, cancer and liver diseases, and is considered to be useful for diagnosis of these diseases. Various measurement methods are currently being developed!
- a measuring method using latex particles as a reagent for measuring hyaluronic acid is described, for example, in Japanese Patent No. 3424504.
- the publication discloses that a hyaluronic acid-binding protein (hyaluronic acid-binding protein) is supported on carrier particles, reacted with hyaluronic acid in a sample to form a reaction mixture, and the resulting mixture is detected to measure hyaluronic acid.
- the method is described, and in the examples, experiments are performed using latex particles having an average particle size of 368 mm.
- latex particles having an average particle diameter of 300 nm (0.3 m) or more are liable to settle. Therefore, when used as a reagent, latex particles usually need to be used after being dispersed by shaking or the like. Therefore, when sedimentation occurs, it is desired to develop a reagent for measuring hyaluronic acid using a carrier such as latex particles, which does not require complicated operations.
- Patent Document 1 Patent No. 3424504 Patent Publication
- the present invention provides a method and a kit for measuring hyaluronic acid using a carrier, in which the sedimentation of the carrier is small, the storage stability thereof is excellent, and the accuracy is as high as conventional reagents.
- the task is to provide
- a hyaluronic acid-binding protein (hereinafter, referred to as an "average particle diameter of 0 or less") hardly sediment, so that a reagent for measuring hyaluronic acid using latex particles can be stored more stably.
- HABP may be abbreviated) by chemical bonding or physical adsorption.
- latex particles were pre-sensitized with a monoclonal antibody against HABP to a latex particle, and a complex of HABP and hyaluronic acid was reacted there. Can be efficiently induced.
- the latex particles sensitized with the monoclonal antibody against HABP and the hyaluronic acid binding protein are stored as separate reagents, and the complex is formed by reacting hyaluronic acid and HABP in advance as described above.
- the reagent can be used as a reagent for measuring hyaluronic acid with excellent storage stability, and the present invention was completed.
- the present invention provides
- the hyaluronic acid in the sample is brought into contact with HABP to form a hyaluronic acid-ZHABP complex, and then the complex is reacted with a carrier carrying an anti-HABP antibody. Measuring the change in hyaluronic acid and calculating the amount of hyaluronic acid measured,
- Reagent kit for measuring hyaluronic acid comprising a reagent comprising HABP and a reagent comprising a carrier carrying an anti-HABP antibody
- the measurement method of the present invention it is possible to perform a simpler measurement than the conventional method, for example, it is not necessary to shake the reagent at the time of use, and to measure hyaluronic acid with the same high accuracy as the conventional reagent Becomes possible.
- the reagent kit of the present invention is excellent in storage stability with little sedimentation of the carrier, and the use of the kit enables highly accurate measurement of hyaluronic acid equivalent to conventional reagents. Can be determined.
- the hyaluronic acid binding protein (HABP) according to the present invention is not particularly limited as long as it includes a hyaluronic acid binding portion in a protein having a property of binding to hyaluronic acid, such as proteodarican, link protein, and hyaluronectin.
- a protein having a property of binding to hyaluronic acid such as proteodarican, link protein, and hyaluronectin.
- the gene for the hyaluronic acid binding portion in the protein may be cut, whether it is the protein itself, a partial protein containing the hyaluronic acid binding portion in the protein, or a substance containing the protein. It may be a recombinant protein or the like obtained by incorporating it into another protein.
- the anti-HABP antibody according to the present invention may be either a polyclonal antibody or a monoclonal antibody as long as it is an antibody against HABP, but a polyclonal antibody or monoclonal antibody prepared by affinity purification of a single epitope is preferable.
- Monoclonal antibodies capable of binding hyaluronic acid efficiently are particularly preferred. Among them, it is preferable to appropriately digest with enzymes such as pepsin and papain and use as Fab, Fa, (Fab ') 2 or the like.
- the antibody can be prepared by a conventional method, such as the method described in “Introduction to Immunology Experiments, Second Printing, Nao Matsuhashi, Gakkai Shuppan Center, 1981” and the like. , Cows, sheep, rabbits, goats, rats, mice, and other animals are immunized with an HA-binding protein.
- a monoclonal antibody is used as an anti-HABP antibody
- the antibody is prepared by a conventional method, According to the cell fusion method established by Stein (G. Kohler and C.
- milstein nature, 256, 495, 1975
- cells from a tumor line of a mouse and splenocytes of a mouse previously immunized with an HA-binding protein were used. It is produced by a hybridoma obtained by fusion.
- any carrier can be used as long as it is a carrier used in a usual immunoassay.
- natural organic high molecular substances such as erythrocytes, bacteria, cell debris and the like can be used.
- Ribosomes, molecular aggregates such as polymer micelles, polystyrene, polyacrylic acid, polymethacrylic acid, polyacrylamide, polyglycidyl methacrylate, polypropylene, polyvinyl chloride, polyethylene, polycarbonate, silicone resin, silicone rubber
- Preferred are those prepared using inorganic substances such as synthetic polymer compounds such as porous glass, ground glass, alumina, silica gel, activated carbon, and metal oxides. .
- These carriers can be used in various forms such as tubes, beads, disc-shaped pieces, fine particles, latex particles, and the like.
- latex particles are artificial carriers, and are particularly preferable in that the surface of the carrier can be easily chemically treated according to the purpose, and nonspecific reaction hardly occurs.
- the material is not particularly limited, for example, styrene-based latex particles such as polystyrene latex particles, acrylic acid-based latex particles, and the like are preferable, and examples thereof include those.
- polystyrene latex particles obtained by emulsion polymerization without using an emulsifier have a strong hydrophobicity on the surface, so that proteins or peptides are smoothly adsorbed and negative charges on the surface are negatively charged. It is particularly preferable because it has a property of being stably dispersed in a solution without an emulsifier, based on the repulsion of the resin.
- modified latex particles for example, carboxylic acid-modified latex particles having a carboxyl group introduced into polystyrene
- magnetic latex particles latex particles containing magnetic particles
- latex particles used in the present invention commercially available latex particles can be used.
- 1S latex particles with a small average particle size that is, those with a large surface area per unit weight, can support antibodies efficiently and have good storage stability (dispersibility in aqueous solution). Since it is used, it is preferably used. More specifically, usually 0.0
- Those having an average particle size of 5 to 0.3 m, preferably 0.1 to 0.25 m are preferred.
- a material having a small average particle size sedimentation of latex particles can be suppressed, and the anti-HABP antibody can be efficiently carried on the latex particles. That is, by using such anti-HABP antibody-supported latex particles, the stability of the measurement reagent is improved, and highly accurate measurement becomes possible.
- the method of supporting the anti-HABP antibody of the present invention on the carrier of the present invention is not particularly limited as long as it is performed by bringing the anti-HABP antibody into contact with the carrier.
- all known loading methods used in this field can be mentioned, for example, a so-called physical adsorption method (physical adsorption method) in which an anti-HABP antibody is physically adsorbed on a carrier and the anti-HABP antibody is loaded on the carrier.
- the method generally includes, for example, synthetic polymer compounds such as polystyrene, polypropylene, polychlorinated vinyl, polyethylene, and polycarbonate carbonate; activated carbon such as porous glass, ground glass, alumina, silica gel, metal oxide, and the like.
- synthetic polymer compounds such as polystyrene, polypropylene, polychlorinated vinyl, polyethylene, and polycarbonate carbonate
- activated carbon such as porous glass, ground glass, alumina, silica gel, metal oxide, and the like.
- an inorganic substance such as hydroxyapatite
- it is particularly preferable to use glass, polystyrene, polyvinyl chloride, or the like in the form of, for example, tubes, beads, disc pieces, fine particles, latex particles, and the like.
- the anti-HABP antibody according to the present invention is usually 0.05 to 2 mg / ml, preferably 0.1 to Lmg / ml.
- the latex particles are usually added and suspended in a solvent such as a buffer solution containing 0.1 ml to 10% (w / v), preferably 0.2 to 5% (w / v).
- a solvent such as a buffer solution containing 0.1 ml to 10% (w / v), preferably 0.2 to 5% (w / v).
- post-treatments performed in this field such as centrifugation, for example, blocking treatment using a solution containing a suitable protein such as bovine serum albumin (BSA), etc.
- BSA bovine serum albumin
- the anti-HABP antibody can be carried on a carrier by using a method using a chemical bond used in this field.
- the method for measuring hyaluronic acid according to the present invention comprises contacting hyaluronic acid in a sample with the HABP according to the present invention to form a hyaluronic acid ZHABP complex, and then forming the complex and the anti-HABP antibody according to the present invention.
- the reaction is carried out by reacting the carrier with the carrier, and the optical change due to the aggregate generated by the reaction is measured, and the measured value is calculated by calculating the amount of hyaluronic acid.
- the measurement of the optical change as used herein refers to the measurement of an optical change resulting from immunoagglutination, and specifically, a reverse passive agglutination reaction method, an immunoflux method, an immunoturbidity method. Immunization coagulation method such as the law. These measurement methods may be performed according to a method known per se.For example, when the reverse passive agglutination method is used, ⁇ Tokyo Kagaku Doujin Seikagaku Kenkyusho 5 Lecture on Immunobiochemistry p.36-37 '' For example, in ⁇ Kinbara Publishing Co., Ltd., Clinical Laboratory Method Proposal, 30th Edition, p. 844-845 '', etc. 853 et al., Etc., use the method described in Kanehara Publishing Co., Ltd., Clinical Laboratory Methods, 30th Edition, p. 853-854, etc. Just do it.
- the measurement method of the present invention will be described below more specifically by taking, for example, an immunoturbidimetric method using latex particles as a carrier. That is, a sample containing hyaluronic acid (more specifically, for example, a body fluid such as blood, plasma, serum, synovial fluid, auxiliary fluid, lymph, bone marrow fluid, urine, etc.) is contacted with a reagent containing HABP as described above. Mix to form hyaluronic acid ZHABP complex. Then, for example, the anti-HABP antibody as described above is loaded on latex particles having an average particle size of 0.05 to 0.3 / zm, preferably 0.1 to 0.25 / zm, and is sensitized.
- hyaluronic acid more specifically, for example, a body fluid such as blood, plasma, serum, synovial fluid, auxiliary fluid, lymph, bone marrow fluid, urine, etc.
- the drug is allowed to react with the above complex, the degree of aggregation that results is measured using, for example, absorbance, and the concentration of the hyaluronic acid in the sample is determined by determining the concentration of the calibration curve of the standard obtained in advance. Is quantified.
- the absorbance may be measured at a wavelength of usually from 340 to 1000 nm, preferably from 500 to 900 nm.
- the degree of aggregation is not limited to the absorbance, and any value may be used as long as it is a method known per se, for example, a method such as nephelometry or counting imnoassay.
- an appropriate An aggregation promoter may be added. Specific examples of such an aggregation promoter will be described in the section of the reagent kit of the present invention.
- the concentration of HABP used in the HABP reaction varies depending on the calibration limit of hyaluronic acid, but the concentration of hyaluronan corresponding to the normally set calibration limit concentration is varied.
- the concentration is at least the concentration capable of binding to all, preferably at least 5 times the concentration, more preferably at least 10 times the concentration.
- the upper limit in this case is not particularly limited as long as it does not affect the measurement. However, considering an economical amount, it is usually 50,000 times or less, preferably 10,000 times or less.
- the calibration limit is usually 10 to LOOOngZml. Therefore, the concentration of HABP used in the HABP reaction should be appropriately set within the above range based on this calibration limit. Just fine.
- the pH during the reaction is not particularly limited as long as it does not prevent the complex from being formed. It is not limited, and usually ranges from 5 to 10, preferably from 6 to 8, and the temperature during the reaction is not particularly limited as long as it does not prevent the complex from being formed, and is usually from 5 to 40. ° C range.
- the reaction time varies depending on the HABP used and the reaction conditions such as pH and temperature, and the reaction may be carried out for several seconds to several hours as appropriate.
- the concentration of the anti-HABP antibody-carrying carrier used in the reaction of the anti-HABP antibody-carrying carrier and the hyaluronic acid ZHABP complex varies depending on the HABP concentration used above. In the case of using latex particles having a loading of HABP antibody of 0.01 to 0.1 mg / mg, it is usually 0.2 to 25 mg / ml, preferably 0.5 to 12 mg / ml, and the concentration is within the range. Then, the hyaluronic acid in the sample can be accurately measured.
- the reaction conditions and reaction time for reacting the anti-HABP antibody-carrying carrier with the hyaluronic acid ZHABP complex may be the same as those for the above-mentioned HABP reaction.
- the reagent kit for measuring hyaluronic acid of the present invention comprises a reagent comprising HABP,
- the reagent kit may contain a standard substance.
- the standard substance may be a substance commonly used in this field. For example, potassium hyaluronate (derived from cockscomb: manufactured by Wako Pure Chemical Industries, Ltd.) And sodium hyaluronate (derived from Streptococcus: Wako Pure Chemical Industries, Ltd.).
- the reagent containing HABP in the reagent kit for measuring hyaluronic acid of the present invention is obtained by dissolving HABP in an appropriate buffer as long as the reagent contains HABP as described above.
- Buffers used for this purpose include, for example, all buffers commonly used in immunoassays, such as Tris buffer, phosphate buffer, veronal buffer, borate buffer, and good buffer.
- the concentration is usually 5 to 300 mM, preferably 10 to 150 mM, and the pH is appropriately selected usually from the range of 5 to 10, preferably 6 to 8.
- the concentration of HABP in the reagent containing HABP varies depending on the type of HABP used, but it is usually 0.1 to 500 ⁇ g as long as the concentration during the reaction is set to be the above concentration. / ml, preferably from 0.5 to 100 ⁇ g / ml.
- the anti-HABP antibody-supporting carrier in the reagent kit for measuring hyaluronic acid of the present invention must not be contained.
- the reagent to be used is a suspension of the anti-HABP antibody-carrying carrier in an appropriate buffer as long as it contains the above-described anti-HABP antibody-carrying carrier, or a lyophilized product thereof.
- the buffer used for this purpose may be any buffer that does not have the property of preventing the anti-HABP antibody of the present invention from binding to HABP, and the buffer used in the above-described reagent containing HABP may be used.
- the same agents as those mentioned above may be mentioned, and their pH and concentration may be similarly set according to the above values.
- the reagent containing the anti-HABP antibody-carrying carrier is often subjected to measurement in the form of a suspension suspended in a solution such as a buffer solution.
- the buffer used for preparing the buffer is not particularly limited as long as it is usually used in this field, but it is usually pH 5.0 to 10.0, preferably pH 6.5 to 8.5. Those having an action, for example, phosphate buffer, Tris buffer, Good buffer and the like are preferable. Depending on the properties of the insoluble fine particles to be used, spontaneous aggregation may easily occur when left in a suspension state.
- a weakly alkaline glycine buffer, boric acid It is preferable to prepare a suspension using a buffer solution or the like in terms of storage stability.
- the buffer concentration of these buffers is appropriately selected usually from the range of 10 to 500 mM, preferably from 10 to 300 mM.
- the reagent may include, for example, stabilizers such as sugars, proteins, and surfactants, salts such as NaCl, and preservatives, which are commonly used in this field. May be added.
- the concentration of the carrier carrying the anti-HABP antibody varies depending on the type of carrier and anti-HABP antibody used. As long as the concentration is set to the above concentration, it is usually selected from 1 to: LOOmg / ml, preferably 2 to 50 mg / ml.
- an immune reaction promoter eg, polyethylene glycol, polybutyl alcohol, etc.
- the protein component in the measurement reagent may be denatured due to some factor and become non-specific even in the presence of these agglutination accelerators. Turbidity can be suppressed or reduced.
- used as an aggregation promoter described in JP-A-2002-365296 is disclosed.
- the concentration range in which the monomer or polymer to be used may be contained as an aggregation promoter may be selected according to the values described in JP-A-2002-365296.
- the monomers and polymers may be prepared according to the method described in the above-mentioned publication.
- the reagent kit for measuring hyaluronic acid of the present invention is used for carrying out the measuring method of the present invention as described above, and preferred embodiments and specific examples of the constituent elements are as described above. is there.
- the sample according to the present invention may be any sample containing hyaluronic acid, and specifically, for example, a body fluid such as blood, plasma, serum, joint fluid, synovial fluid, lymph, bone marrow fluid, or the like.
- a body fluid such as blood, plasma, serum, joint fluid, synovial fluid, lymph, bone marrow fluid, or the like.
- Urine and the like are mentioned, and among them, serum, urine and the like are preferable.
- hyaluronic acid-binding protein purified from Pepsi nasal septum cartilage by a modified method of Laurent et al. (Manufactured by Seikagaku Corporation) was added to 10 ml of lOOmM HEPES buffer solution (0.1% BSA and l% NaCl, pH 7.0). This was used as the first test solution in Example.
- purified water 800 1, latex particle solution 100 1 (N200 manufactured by Sekisui Chemical Co., Ltd .: N200: 10 wt%, latex particle size 220 nm), 500 mM borate buffer (pH 7.3) 100 ⁇ l, Add 50 mM anti-HABP monoclonal antibody ASES buffer 100 1 (4.24 mg / ml, pH 6.5), and incubate at room temperature for 100 minutes with stirring to remove the latex particle suspension carrying the anti-HABP monoclonal antibody. Obtained.
- the anti-HABP monoclonal antibody used was one prepared by a conventional method.
- the suspension of latex particles carrying the anti-HABP monoclonal antibody was centrifuged at 15,000 rpm for 15 minutes. Remove the supernatant, add 1 ml of 50 mM borate buffer (containing 2.5% BSA, pH 7.3) to the pellet at the bottom of the container, and sonicate for 1 minute while cooling on ice to resuspend the pellet. Was. Then centrifuged at 15000 rpm for 15 minutes. The supernatant was removed, and 1 ml of 50 mM borate buffer (containing 2.5% BSA, pH 7.3) was added to the pellet at the bottom of the container. Thereafter, the pellet was resuspended by sonication for 1 minute while cooling on ice. Further, the mixture was incubated at room temperature for 120 minutes while stirring, and the antibody was supported on the surface of the latex particles. The remaining area was covered with BSA.
- 50 mM borate buffer containing 2.5% BSA, pH 7.3
- Potassium hyaluronate (manufactured by Wako Pure Chemical Industries, Ltd.) was diluted with a 50 mM phosphate buffer (pH 7.0) to a concentration of 10, 100, or 1000 ng / ml to obtain a standard hyaluronic acid solution.
- the amount of hyaluronic acid in the standard hyaluronic acid solution prepared in 1. was measured using a fully automatic measuring system (JEOL: BM-8) under the following measurement conditions.
- Measurement method 2-point end method
- Table 1 shows the obtained results.
- the values in the table are values obtained by subtracting the blank value (value obtained when the hyaluronic acid concentration is 0) from the obtained absorbance power and multiplying it by 10,000.
- reaction solution was centrifuged at 18000 rpm for 20 minutes. The supernatant was removed, and the pellet at the bottom of the vessel was added with 1 ml of 50 mM borate buffer (containing 0.5% BSA, pH 7.3). afterwards
- the pellet was resuspended by sonication for 1 minute while cooling on ice, and the same operation was repeated twice more.
- the obtained solution was used as a second test solution (1).
- HABP-sensitized latex particles were prepared in the same manner as in Comparative Example 1, except that a carboxylic acid latex particle solution of 10 wt%, 210 nm, and a carboxylic acid content of 0.5 meqZg was used. The obtained solution was used as a second reagent (2).
- the reaction was then centrifuged at 15000 rpm for 15 minutes. The supernatant was removed, and the pellet at the bottom of the vessel was added with 1 ml of 50 mM borate buffer (containing 2.5% BSA, pH 7.3). Then, the mixture was sonicated for 1 minute while cooling on ice, and the pellet was resuspended. It was then centrifuged at 15000 rpm for 15 minutes. The supernatant was removed, and 1 ml of 50 mM borate buffer (containing 2.5% BSA, pH 7.3) was added to the pellet at the bottom of the container. Furthermore, the pellet was resuspended by sonication for 1 minute while cooling on ice, incubated at room temperature for 60 minutes with stirring, and then incubated at 5 ° C overnight.
- 50 mM borate buffer containing 2.5% BSA, pH 7.3
- LOOmMHEPES buffer (0.1% BSA, containing l% NaCl, pH 7.0) as the first reagent, and 2nd reagents (1) to (4) as the second reagent, 50 mM borate buffer (containing 0.5% BSA, pH7)
- the amount of hyaluronic acid in the standard hyaluronic acid solution was measured in the same manner as in Example 1 (2) except that it was used after diluting 3.33 times in .3).
- the first reagent solution and the second reagent solution used in Example 1 were stored at 30 ° C. for one month, and the amount of hyaluronic acid was measured using the reagent solution in the same manner as in Example 1 (2). Further, the first TS used in Comparative Example 1 and the second TS (4) of Comparative Example 1 were stored at 30 ° C for one month, and the hyaluronic acid was used using the TS in the same manner as in Comparative Example 1 (5). The amount was measured.
- Table 2 shows the obtained measurement results.
- the value in the absorbance column in the table is a value obtained by subtracting a blank value (a value obtained when the hyaluronic acid concentration is 0) from the obtained absorbance and multiplying it by 10,000.
- the retention of absorbance is a value obtained by dividing the obtained absorbance by the absorbance measured before incubation for one month, and expressed as a percentage.
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05739187A EP1752767B1 (en) | 2004-05-20 | 2005-05-10 | Method of assaying hyaluronic acid by using hyaluronic acid-binding protein |
US11/597,191 US20070259380A1 (en) | 2004-05-20 | 2005-05-10 | Method for Measuring Hyaluronic Acid Using Hyaluronic Acid Binding Protein |
AT05739187T ATE516498T1 (de) | 2004-05-20 | 2005-05-10 | Verfahren zum testen von hyaluronsäure mit hyaluronsäure-bindungsprotein |
JP2006513682A JP4730304B2 (ja) | 2004-05-20 | 2005-05-10 | ヒアルロン酸バインディングプロテインを用いたヒアルロン酸の測定方法 |
US12/578,576 US20100129937A1 (en) | 2004-05-20 | 2009-10-13 | Method for measuring hyaluronic acid using hyaluronic acid binding protein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004149940 | 2004-05-20 | ||
JP2004-149940 | 2004-05-20 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/578,576 Division US20100129937A1 (en) | 2004-05-20 | 2009-10-13 | Method for measuring hyaluronic acid using hyaluronic acid binding protein |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005114186A1 true WO2005114186A1 (ja) | 2005-12-01 |
Family
ID=35428488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/008523 WO2005114186A1 (ja) | 2004-05-20 | 2005-05-10 | ヒアルロン酸バインディングプロテインを用いたヒアルロン酸の測定方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20070259380A1 (ja) |
EP (1) | EP1752767B1 (ja) |
JP (2) | JP4730304B2 (ja) |
AT (1) | ATE516498T1 (ja) |
ES (1) | ES2368335T3 (ja) |
WO (1) | WO2005114186A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009128448A1 (ja) * | 2008-04-15 | 2009-10-22 | 和光純薬工業株式会社 | 新規なヒアルロン酸結合能を有するタンパク質及びこれを用いたヒアルロン酸の測定方法 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170074868A1 (en) * | 2009-12-20 | 2017-03-16 | Astute Medical, Inc. | Methods and compositions for the evaluation of renal injury using hyaluronic acid |
US20130252264A1 (en) * | 2010-09-24 | 2013-09-26 | Astute Medical, Inc. | Methods and compositions for the evaluation of renal injury using hyaluronic acid |
LT2661276T (lt) * | 2011-01-07 | 2017-12-11 | Revance Therapeutics, Inc. | Paviršinio naudojimo kompozicija, apimanti botulino toksiną ir dažą |
US20150241415A1 (en) * | 2012-08-11 | 2015-08-27 | Astute Medical, Inc. | Evaluating renal injury using hyaluronic acid |
CN106093373A (zh) * | 2016-05-27 | 2016-11-09 | 安徽伊普诺康生物技术股份有限公司 | 一种测定透明质酸的试剂盒 |
CN106198994A (zh) * | 2016-06-22 | 2016-12-07 | 浙江达美生物技术有限公司 | 一种透明质酸的测定试剂及其制备方法 |
MX2019001651A (es) | 2016-08-10 | 2019-09-04 | Univ Ajou Ind Academic Coop Found | Citocina fusionada a fc heterodimerico, y composicion farmaceutica que comprende la misma. |
TW202033547A (zh) | 2018-10-23 | 2020-09-16 | 美商蜻蜓醫療公司 | 異二聚體fc融合蛋白 |
AU2021260960A1 (en) | 2020-04-22 | 2022-11-24 | Dragonfly Therapeutics, Inc. | Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins |
CN113433064A (zh) * | 2021-05-29 | 2021-09-24 | 北京华宇亿康生物工程技术有限公司 | 一种透明质酸检测试剂盒及其方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0541946A (ja) | 1991-08-13 | 1993-02-23 | Miyamura Tekkosho:Kk | 生茶葉の蒸熱処理法 |
JPH08193999A (ja) | 1995-01-13 | 1996-07-30 | Sekisui Chem Co Ltd | 免疫測定法 |
JPH1114628A (ja) | 1997-06-24 | 1999-01-22 | Mitsubishi Chem Corp | タンパク質又はリガンドの測定方法 |
JP2002365296A (ja) | 2001-06-05 | 2002-12-18 | Wako Pure Chem Ind Ltd | 免疫学的測定法用凝集促進剤 |
WO2002101389A1 (fr) | 2001-06-12 | 2002-12-19 | Wako Pure Chemical Industries, Ltd. | Procede de dosage de l'acide hyaluronique |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55162059A (en) * | 1979-06-05 | 1980-12-17 | Mochida Pharmaceut Co Ltd | Measuring method for antigen, antibody or their complex and measurement reagent kit |
SE8605270D0 (sv) * | 1986-12-08 | 1986-12-08 | Pharmacia Ab | Hyaluronsyrabestemningsmetod och reagenssats for anvendning vid metoden |
CA1312277C (en) * | 1987-12-18 | 1993-01-05 | Richard C. Sutton | Avidin- and biotin-immobilized reagents, analytical elements and methods of use |
IE75720B1 (en) * | 1990-10-08 | 1997-09-24 | Akzo Nv | Device for performing a rapid single manual assay |
TW239881B (ja) * | 1992-12-22 | 1995-02-01 | Sienna Biotech Inc | |
US5863502A (en) * | 1996-01-24 | 1999-01-26 | Sarnoff Corporation | Parallel reaction cassette and associated devices |
JP3976848B2 (ja) * | 1996-07-16 | 2007-09-19 | 生化学工業株式会社 | 血清由来ヒアルロナン結合性タンパク質−ヒアルロン酸結合体の測定法および測定キット |
JP4124526B2 (ja) * | 1998-10-07 | 2008-07-23 | 生化学工業株式会社 | 正常アグリカン測定法とその応用 |
JP2002202310A (ja) * | 2000-10-27 | 2002-07-19 | Morinaga Milk Ind Co Ltd | 物質の検出試薬及び検出方法 |
-
2005
- 2005-05-10 WO PCT/JP2005/008523 patent/WO2005114186A1/ja not_active Application Discontinuation
- 2005-05-10 AT AT05739187T patent/ATE516498T1/de not_active IP Right Cessation
- 2005-05-10 EP EP05739187A patent/EP1752767B1/en active Active
- 2005-05-10 US US11/597,191 patent/US20070259380A1/en not_active Abandoned
- 2005-05-10 ES ES05739187T patent/ES2368335T3/es active Active
- 2005-05-10 JP JP2006513682A patent/JP4730304B2/ja active Active
-
2009
- 2009-10-13 US US12/578,576 patent/US20100129937A1/en not_active Abandoned
-
2010
- 2010-12-06 JP JP2010271682A patent/JP5273134B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0541946A (ja) | 1991-08-13 | 1993-02-23 | Miyamura Tekkosho:Kk | 生茶葉の蒸熱処理法 |
JPH08193999A (ja) | 1995-01-13 | 1996-07-30 | Sekisui Chem Co Ltd | 免疫測定法 |
JPH1114628A (ja) | 1997-06-24 | 1999-01-22 | Mitsubishi Chem Corp | タンパク質又はリガンドの測定方法 |
JP3424504B2 (ja) | 1997-06-24 | 2003-07-07 | 三菱化学株式会社 | ヒアルロン酸結合タンパク質又はヒアルロン酸の測定方法 |
JP2002365296A (ja) | 2001-06-05 | 2002-12-18 | Wako Pure Chem Ind Ltd | 免疫学的測定法用凝集促進剤 |
WO2002101389A1 (fr) | 2001-06-12 | 2002-12-19 | Wako Pure Chemical Industries, Ltd. | Procede de dosage de l'acide hyaluronique |
Non-Patent Citations (6)
Title |
---|
"A Manual of Clinical Laboratory Method", KANEHARA & CO. , LTD., pages: 853 - 854 |
"A Manual of Clinical Laboratory Method", KANEHARA & CO., LTD., pages: 844 - 845 |
"A Manual of Clinical Laboratory Test", KANEHARA & CO., LTD., pages: 851 - 853 |
"Successive Course on Biochemical Experiment 5: Investigative Approach to Immunobiochemistry", TOKYO KAGAKU DOJIN CO., LTD., pages: 36 - 37 |
G. KOHLER; C. MILSTEIN, NATURE, vol. 256, 1975, pages 495 |
MATSUHASHI, T. ET AL.: "Introduction to Experimental Immunology", 1981, JAPAN SCIENTIFIC SOCIETIES PRESS |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009128448A1 (ja) * | 2008-04-15 | 2009-10-22 | 和光純薬工業株式会社 | 新規なヒアルロン酸結合能を有するタンパク質及びこれを用いたヒアルロン酸の測定方法 |
US8034630B2 (en) | 2008-04-15 | 2011-10-11 | Wako Pure Chemical Industries, Ltd. | Protein capable of binding to hyaluronic acid, and method for measurement of hyaluronic acid using the same |
JP5477287B2 (ja) * | 2008-04-15 | 2014-04-23 | 和光純薬工業株式会社 | 新規なヒアルロン酸結合能を有するタンパク質及びこれを用いたヒアルロン酸の測定方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1752767B1 (en) | 2011-07-13 |
EP1752767A4 (en) | 2008-10-15 |
US20070259380A1 (en) | 2007-11-08 |
JPWO2005114186A1 (ja) | 2008-03-27 |
ATE516498T1 (de) | 2011-07-15 |
JP4730304B2 (ja) | 2011-07-20 |
US20100129937A1 (en) | 2010-05-27 |
JP2011090004A (ja) | 2011-05-06 |
ES2368335T3 (es) | 2011-11-16 |
JP5273134B2 (ja) | 2013-08-28 |
EP1752767A1 (en) | 2007-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005114186A1 (ja) | ヒアルロン酸バインディングプロテインを用いたヒアルロン酸の測定方法 | |
JPS60256057A (ja) | 免疫学的測定法 | |
JP4668768B2 (ja) | 免疫測定方法及び非特異反応抑制方法 | |
CN108593641B (zh) | 一种定量检测全血样品中待测物质的试剂盒及方法 | |
CN110007074B (zh) | 用于检测c反应蛋白的试剂盒、其制备方法及用途 | |
US20100233734A1 (en) | Passivation of surfaces after ligand coupling | |
JP3623657B2 (ja) | 非特異反応抑制剤、免疫測定試薬及び免疫測定方法 | |
JP6515923B2 (ja) | クレアチンキナーゼmbアイソザイムの測定方法及びそれに用いられるキット | |
JPWO2002048711A1 (ja) | 免疫学的分析試薬及び分析方法 | |
JP4086266B2 (ja) | 免疫測定方法 | |
JP2016031250A (ja) | 標的タンパク質の測定試薬および該試薬を用いた測定方法 | |
JP2001512574A (ja) | ハプトグロビンの表現型を決定する方法およびキットならびにその使用 | |
JP4353856B2 (ja) | 免疫学的測定試薬 | |
JP2004325414A (ja) | 免疫測定方法及び免疫測定キット | |
JPH0712818A (ja) | 免疫学的検出方法 | |
JP2003344410A (ja) | 免疫測定試薬及び免疫測定法 | |
JP3598701B2 (ja) | 不溶性担体を用いた免疫化学的測定方法 | |
JP3328053B2 (ja) | 免疫凝集反応による抗体又は抗原の濃度定量法 | |
JP3464357B2 (ja) | 免疫学的凝集反応試薬の製造方法 | |
JP2545503B2 (ja) | 免疫学的診断試薬 | |
JP3220545B2 (ja) | リューマチ性因子決定法および該方法実施用試薬 | |
JPH0750110B2 (ja) | 免疫測定法 | |
JP2001305137A (ja) | 特異的複合体の固定化方法および測定方法 | |
JP2003215128A (ja) | 免疫体固定化高分子ラテックス | |
JPH07270423A (ja) | 免疫診断薬の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006513682 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005739187 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11597191 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005739187 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11597191 Country of ref document: US |